Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
AstraZeneca downgraded to Hold from Buy at Kepler Cheuvreux » 05:13
05/18/22
05/18
05:13
05/18/22
05:13
AZN

AstraZeneca

$65.65 /

+1.15 (+1.78%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$65.65 /

+1.15 (+1.78%)

AZN AstraZeneca
$65.65 /

+1.15 (+1.78%)

04/21/22 Morgan Stanley
AstraZeneca price target raised to 11,100 GBp from 10,200 GBp at Morgan Stanley
04/14/22 Barclays
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Barclays
04/12/22 Piper Sandler
Schrodinger has 'potent and highly selective' molecule , says Piper Sandler
04/08/22 Credit Suisse
AstraZeneca price target raised to 11,000 GBp from 9,000 GBp at Credit Suisse
AZN AstraZeneca
$65.65 /

+1.15 (+1.78%)

AZN AstraZeneca
$65.65 /

+1.15 (+1.78%)

AZN AstraZeneca
$65.65 /

+1.15 (+1.78%)

AZN AstraZeneca
$65.65 /

+1.15 (+1.78%)

Conference/Events
Aziyo Biologics management to meet virtually with Piper Sandler » 04:55
05/18/22
05/18
04:55
05/18/22
04:55
AZYO

Aziyo Biologics

$6.89 /

+0.59 (+9.37%)

Virtual meetings with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZYO Aziyo Biologics
$6.89 /

+0.59 (+9.37%)

AZYO Aziyo Biologics
$6.89 /

+0.59 (+9.37%)

03/04/22 Cowen
Aziyo Biologics price target lowered to $13 from $15 at Cowen
03/03/22 Piper Sandler
Aziyo Biologics price target lowered to $9 from $11 at Piper Sandler
11/09/21 Piper Sandler
Aziyo Biologics price target lowered to $11 from $14 at Piper Sandler
10/25/21 Piper Sandler
Medtronic exit from Aziyo Biologics deal not unexpected, says Piper Sandler
AZYO Aziyo Biologics
$6.89 /

+0.59 (+9.37%)

Yesterday
Hot Stocks
Medtronic announces data on Symplicity Blood Pressure Procedure with RDN » 08:07
05/17/22
05/17
08:07
05/17/22
08:07
MDT

Medtronic

$103.80 /

+1.14 (+1.11%)

Medtronic announced data…

Medtronic announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral Renal Denervation, or RDN, system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17. Time in target range, or TTR, plays an important role in the management of many chronic diseases, such as diabetes and hypertension, measuring how well a parameter is controlled in patients. Specifically, for hypertension, increasing TTR has been shown to be an independent predictor of reductions in cardiovascular risks, including stroke, heart attack, and death.

ShowHide Related Items >><<
MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

05/17/22 Citi
Medtronic price target lowered to $120 from $127 at Citi
04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Medtronic assumed at Hold from Buy at Truist
MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

Hot Stocks
Accuray appoints Sandeep Chalke as Chief Commercial Officer » 07:36
05/17/22
05/17
07:36
05/17/22
07:36
ARAY

Accuray

$2.26 /

-0.05 (-2.16%)

, MDT

Medtronic

$103.80 /

+1.14 (+1.11%)

Accuray (ARAY) announced…

Accuray (ARAY) announced that Sandeep Chalke has joined the company as senior vice president, Chief Commercial Officer effective May 16. Chalke will have responsibility for the global commercial, product development, R&D and engineering functions for the company reporting to Accuray president and forthcoming CEO, Suzanne Winter. Chalke brings more than 25 years of medical device expertise in commercialization, business development and operations, spanning multiple healthcare industry segments including interventional catheterization systems, diagnostic x-ray, C-arm linear accelerators, anesthesia and respiratory care, advanced wound dressing & diabetes. Most recently, he served as president, Asia-Pacific and Latin America regions at Vyaire Medical, a global respiratory care manufacturer, where he had full P&L responsibility along with oversight of select manufacturing sites. Prior to Vyaire, Chalke held various global leadership positions at Medtronic (MDT), Acelity. and GE Healthcare, where he led the development of new products and service solutions, established new markets and partnerships with government organizations and private payors to drive revenue growth, margin expansion and technology leadership.

ShowHide Related Items >><<
MDT Medtronic
$103.80 /

+1.14 (+1.11%)

ARAY Accuray
$2.26 /

-0.05 (-2.16%)

ARAY Accuray
$2.26 /

-0.05 (-2.16%)

12/21/21 Loop Capital
Loop starts Accuray at Buy, sees 'major opportunity in China'
12/21/21 Loop Capital
Accuray initiated with a Buy at Loop Capital
10/26/21 Lake Street
Investors should buy Accuray after 'excellent' ASTRO meeting, says Lake Street
MDT Medtronic
$103.80 /

+1.14 (+1.11%)

05/17/22 Citi
Medtronic price target lowered to $120 from $127 at Citi
04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Medtronic assumed at Hold from Buy at Truist
MDT Medtronic
$103.80 /

+1.14 (+1.11%)

ARAY Accuray
$2.26 /

-0.05 (-2.16%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

Recommendations
Zimmer Biomet price target lowered to $125 from $135 at Citi » 06:27
05/17/22
05/17
06:27
05/17/22
06:27
ZBH

Zimmer Biomet

$115.08 /

+0.1 (+0.09%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch lowered the firm's price target on Zimmer Biomet to $125 from $135 and keeps a Neutral rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$115.08 /

+0.1 (+0.09%)

ZBH Zimmer Biomet
$115.08 /

+0.1 (+0.09%)

05/04/22 Truist
Zimmer Biomet price target lowered to $131 from $142 at Truist
05/03/22 Stifel
Zimmer Biomet price target raised to $140 from $130 at Stifel
05/03/22 Piper Sandler
Piper raises Zimmer Biomet target to $130, but sees 'better large caps to own'
04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
ZBH Zimmer Biomet
$115.08 /

+0.1 (+0.09%)

ZBH Zimmer Biomet
$115.08 /

+0.1 (+0.09%)

ZBH Zimmer Biomet
$115.08 /

+0.1 (+0.09%)

Recommendations
Medtronic price target lowered to $120 from $127 at Citi » 06:26
05/17/22
05/17
06:26
05/17/22
06:26
MDT

Medtronic

$103.80 /

+1.14 (+1.11%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch lowered the firm's price target on Medtronic to $120 from $127 and keeps a Buy rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch.

ShowHide Related Items >><<
MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Medtronic assumed at Hold from Buy at Truist
03/01/22 BofA
Medtronic reinstated with a Buy at BofA
MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

MDT Medtronic
$103.80 /

+1.14 (+1.11%)

Recommendations
Intuitive Surgical price target lowered to $305 from $360 at Citi » 06:25
05/17/22
05/17
06:25
05/17/22
06:25
ISRG

Intuitive Surgical

$219.47 /

-4.09 (-1.83%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch lowered the firm's price target on Intuitive Surgical to $305 from $360 and keeps a Buy rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$219.47 /

-4.09 (-1.83%)

ISRG Intuitive Surgical
$219.47 /

-4.09 (-1.83%)

04/22/22 Evercore ISI
Intuitive Surgical price target lowered to $280 from $294 at Evercore ISI
04/22/22 Raymond James
Intuitive Surgical price target lowered to $330 from $334 at Raymond James
04/22/22 Bernstein
Bernstein calls Intuitive Surgical 'top pick,' would buy on weakness
04/22/22 Piper Sandler
Intuitive Surgical price target raised to $316 from $310 at Piper Sandler
ISRG Intuitive Surgical
$219.47 /

-4.09 (-1.83%)

ISRG Intuitive Surgical
$219.47 /

-4.09 (-1.83%)

ISRG Intuitive Surgical
$219.47 /

-4.09 (-1.83%)

ISRG Intuitive Surgical
$219.47 /

-4.09 (-1.83%)

Recommendations
Edwards Lifesciences price target lowered to $115 from $134 at Citi » 06:25
05/17/22
05/17
06:25
05/17/22
06:25
EW

Edwards Lifesciences

$95.92 /

-1.68 (-1.72%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch lowered the firm's price target on Edwards Lifesciences to $115 from $134 and keeps a Buy rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch.

ShowHide Related Items >><<
EW Edwards Lifesciences
$95.92 /

-1.68 (-1.72%)

EW Edwards Lifesciences
$95.92 /

-1.68 (-1.72%)

04/27/22 Canaccord
Edwards Lifesciences price target lowered to $137 from $152 at Canaccord
04/27/22 Citi
Edwards Lifesciences price target lowered to $134 from $138 at Citi
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Edwards Lifesciences initiated with a Buy at Truist
EW Edwards Lifesciences
$95.92 /

-1.68 (-1.72%)

EW Edwards Lifesciences
$95.92 /

-1.68 (-1.72%)

EW Edwards Lifesciences
$95.92 /

-1.68 (-1.72%)

Recommendations
Abbott price target lowered to $125 from $154 at Citi » 06:24
05/17/22
05/17
06:24
05/17/22
06:24
ABT

Abbott

$109.76 /

-0.17 (-0.15%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch lowered the firm's price target on Abbott to $125 from $154 and keeps a Buy rating on the shares. Market multiples are contracting due to higher inflation, slowing growth, and rising interest rates, Wuensch tells investors in a research note. What we don't know yet is how far the derating will go and where does medical technology shake out, balancing an elective procedure recovery with macro headwinds, says the analyst. "When is the right time to catch a falling knife? If recent history is any suggestion, the answer could be 'soon,'" writes Wuensch.

ShowHide Related Items >><<
ABT Abbott
$109.76 /

-0.17 (-0.15%)

ABT Abbott
$109.76 /

-0.17 (-0.15%)

04/21/22 Raymond James
Abbott price target lowered to $135 from $143 at Raymond James
04/08/22 Wells Fargo
Abbott price target lowered to $150 from $155 at Wells Fargo
03/01/22 BofA
Abbott reinstated with a Buy at BofA
02/02/22 Piper Sandler
Boston Scientific thesis unchanged despite margin outlook, says Piper Sandler
ABT Abbott
$109.76 /

-0.17 (-0.15%)

ABT Abbott
$109.76 /

-0.17 (-0.15%)

ABT Abbott
$109.76 /

-0.17 (-0.15%)

ABT Abbott
$109.76 /

-0.17 (-0.15%)

Monday
Hot Stocks
Abbott announces efforts to support formula supply since recall » 16:35
05/16/22
05/16
16:35
05/16/22
16:35
ABT

Abbott

$109.76 /

-0.17 (-0.15%)

Since the recall, the…

Since the recall, the company has taken numerous measures to mitigate the supply shortage. Specifically, it has focused on production in its Cootehill, Ireland, facility to serve state Special Supplemental Nutrition Program for Women, Infants and Children consumers. Abbott has been working with the U.S. Department of Agriculture and WIC agencies and paying rebates on competitive products in states where Abbott holds the WIC contract, when Similac is not available. Abbott said Friday it will continue to pay rebates for competitive products through August 31. This means program participants will continue to be able to obtain formula free of charge, whether it is Similac or formula from another manufacturer. Additionally, the company has: Air shipped millions of cans of infant formula powder into the U.S. from our FDA-registered facility in Cootehill, Ireland. Prioritized infant formula production at our Columbus, Ohio, facility, converting other liquid manufacturing lines into manufacturing Similac liquid ready-to-feed and ramped production at our other U.S. manufacturing site in Casa Grande, Arizona, for powder infant formula. Offered an increased number and value of coupons available for all infant formula products, including Similac liquid ready-to-feed, to enable customers to purchase formula, either free or deeply discounted. Been running other facilities at full capacity to help replenish the supply in the market.

ShowHide Related Items >><<
ABT Abbott
$109.76 /

-0.17 (-0.15%)

ABT Abbott
$109.76 /

-0.17 (-0.15%)

04/21/22 Raymond James
Abbott price target lowered to $135 from $143 at Raymond James
04/08/22 Wells Fargo
Abbott price target lowered to $150 from $155 at Wells Fargo
03/01/22 BofA
Abbott reinstated with a Buy at BofA
02/02/22 Piper Sandler
Boston Scientific thesis unchanged despite margin outlook, says Piper Sandler
ABT Abbott
$109.76 /

-0.17 (-0.15%)

ABT Abbott
$109.76 /

-0.17 (-0.15%)

ABT Abbott
$109.76 /

-0.17 (-0.15%)

ABT Abbott
$109.76 /

-0.17 (-0.15%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.